Clls stock price

CLLS - Cellectis S.A. ADR Stock Price - Barchart.com It is based on a 60-month historical regression of the return on the stock onto the return on the S&P 500. Price/Sales: Latest closing price divided by the last 12 months of revenue/sales per share. Price/Cash Flow: Latest closing price divided by the last 12 months revenue/cash flow per share.

Cellectis S.A. American Depositary Shares (CLLS) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. CLLS, Cellectis S A Ads - Stock quote performance, technical chart analysis, SmartSelect Ratings, Group Leaders and the latest company headlines. Close 8.33; Price Open; Volume 0; Day's Range -; 52 Wk Range 7.32 - 20.84; 50 Day Moving Avg. 13.7; PE Ratio 0; Shares Outstanding 42.47M; Market Cap  Stock analysis for Cellectis SA (CLLS:NASDAQ GM) including stock price, stock chart, company news, key statistics, fundamentals and company profile.

Cellectis - CLLS - Stock Price & News | The Motley Fool

View the latest Cellectis S.A. ADR (CLLS) stock price, news, historical charts, analyst ratings and financial information from WSJ. CLLS Stock Quote - Cellectis S.A. American Depositary ... Mar 27, 2020 · Stock quote for Cellectis S.A. American Depositary Shares Common Stock (CLLS) with real-time last sale and extended hours stock prices, company news, charts, and research at Nasdaq. CLLS - Cellectis S.A. ADR Stock Price - Barchart.com It is based on a 60-month historical regression of the return on the stock onto the return on the S&P 500. Price/Sales: Latest closing price divided by the last 12 months of revenue/sales per share. Price/Cash Flow: Latest closing price divided by the last 12 months revenue/cash flow per share. CLLS - Cellectis SA Stock quote - CNNMoney.com

Current, Vs Industry, Vs History. 3-Year Average Share Buyback Ratio, -6.3. Valuation & Return. Current, Vs Industry, Vs History. Price-to-Tangible-Book, 1.2.

Cellectis S.A. (CLLS) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. Apr CLLS Stock Price, Forecast & News (Cellectis) | MarketBeat 5 Wall Street analysts have issued 1-year price targets for Cellectis' shares. Their forecasts range from $11.00 to $73.00. On average, they anticipate Cellectis' share price to reach $34.75 in the next year. This suggests a possible upside of 303.6% from the stock's current … Cellectis S.A. American Depositary Shares (CLLS) Stock ...

Dec 19, 2019 Cellectis SA (CLLS) stock is trading at $19.49 as of 10:00 AM on Thursday, Dec 19, a rise of $0.18, or 0.93% from the previous closing price of 

Cellectis (CLLS) stock price, charts, trades & the US's most popular discussion forums. Free forex prices, toplists, indices and lots more. Cellectis S.A. (CLLS) stock price, quote, history & news ... Find the latest Cellectis S.A. (CLLS) stock quote, history, news and other vital information to help you with your stock trading and investing. CLLS - Stock quote for Cellectis SA - MSN Money

Cellectis is developing the first of its kind allogeneic approach for CAR-T immunotherapies in oncology, pioneering the concept of off-the-shelf and ready-to-use gene-edited CAR T-cells to treat cancer patients.

View the latest CLLS stock quote and chart on MSN Money. Dive deeper with interactive charts and top stories of Cellectis SA. CLLS: Cellectis Stock Price - Investing.com CLLS Overview This is the main Cellectis SA stock chart and current price. You can find more details by going to one of the sections under this page such as historical data, charts, technical Cellectis SA (CLLS) Stock Price Chart - History & Analysis ...

Trade-Ideas: Cellectis (CLLS) Is Today's Weak On High Relative Volume Stock. By TheStreet Wire. Jul 8, 2016 10:33 AM EDT. VIDEO. CEOs Should Set Tone for Corporate Culture. By Rhonda Schaffler. CLLS Cellectis S.A. Stock Quote - FINVIZ.com ETFs with exposure to Cellectis SA : November 15, 2017 Capital Cube Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells.